keyword
MENU ▼
Read by QxMD icon Read
search

Rheumatic heart disease heart failure rct

keyword
https://www.readbyqxmd.com/read/22895944/short-term-late-generation-antibiotics-versus-longer-term-penicillin-for-acute-streptococcal-pharyngitis-in-children
#1
REVIEW
Saleh Altamimi, Adli Khalil, Khalid A Khalaiwi, Ruth A Milner, Martin V Pusic, Mohammed A Al Othman
BACKGROUND: The standard duration of treatment for children with acute group A beta hemolytic streptococcus (GABHS) pharyngitis with oral penicillin is 10 days. Shorter duration antibiotics may have comparable efficacy. OBJECTIVES: To summarize the evidence regarding the efficacy of two to six days of newer oral antibiotics (short duration) compared to 10 days of oral penicillin (standard duration) in treating children with acute GABHS pharyngitis. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2012, Issue 3) which contains the Cochrane Acute Respiratory Infections Group's Specialized Register, MEDLINE (January 1966 to March week 3, 2012) and EMBASE (January 1990 to April 2012)...
2012: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/20428001/diuretic-therapy-in-fluid-overloaded-and-heart-failure-patients
#2
REVIEW
Rinaldo Bellomo, John R Prowle, Jorge E Echeverri
Diuretics are the most commonly used drugs to treat clinically diagnosed fluid overload in patients with heart failure. There is no conclusive evidence that they alter major outcomes such as survival to hospital discharge or time in hospital compared to other therapies. However, they demonstrably achieve fluid removal in the majority of patients, restore dry body weight, improve the breathlessness of pulmonary edema and are unlikely to be subjected to a large double-blind randomized controlled trial in this setting because of lack of equipoise...
2010: Contributions to Nephrology
https://www.readbyqxmd.com/read/19160243/short-versus-standard-duration-antibiotic-therapy-for-acute-streptococcal-pharyngitis-in-children
#3
REVIEW
Saleh Altamimi, Adli Khalil, Khalid A Khalaiwi, Ruth Milner, Martin V Pusic, Mohammed A Al Othman
BACKGROUND: The standard duration of treatment for acute group A beta hemolytic streptococcus (GABHS) pharyngitis with oral penicillin is 10 days. Shorter duration antibiotics may have comparable efficacy. OBJECTIVES: To summarize the evidence regarding the efficacy of two to six days of newer oral antibiotics (short duration) compared to 10 days of oral penicillin (standard duration) in treating children with acute GABHS pharyngitis. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, issue 4), which contains the Acute Respiratory Infections Group's Specialized Register; the Database of Abstracts of Reviews of Effects (DARE); MEDLINE (1966 to October 2007); OLDMEDLINE (1950 to December 1965); and EMBASE (January 1990 to November 2007)...
2009: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/18846476/mitral-valve-surgery-a-scandinavian-perspective
#4
EDITORIAL
Truls Myrmel, Marius Roaldsen
During the last three decades, the most prevalent surgical mitral valve disease in Scandinavia has changed from the sequelae of rheumatic fever to the mitral valve pathologies related to ischemic heart disease. Also, the total number of patients in need of a mitral valve procedure is increasing. For several of the patients with ischemic mitral valve disease, the natural prognosis of their disease is dismal. However, there are several uncertainties as to whether or not a surgical procedure can improve the life expectancies of these patients...
February 2009: Scandinavian Cardiovascular Journal: SCJ
https://www.readbyqxmd.com/read/17078594/-how-to-watch-over-a-patient-treated-with-a-nsaid-in-relation-to-the-cardiovascular-and-renal-risk
#5
COMPARATIVE STUDY
Thierry Schaeverbeke, François Héloire, Gilbert Deray
Despite the cardiovascular risk attributable to the NSAIDs, these drugs are among the most prescribed treatments in the world. Recently to manage this risk during chronic inflammatory rheumatisms a surveillance plan has been developed based on a decision algorithm. Given that the arterial thrombotic risks (myocardial or cerebral) are observed essentially during long-term treatments, two types of situation have been envisaged, short-term treatments and long-term treatments. Before any short-term NSAID prescription (less than one month), the cardio-renal risk should be evaluated...
September 2006: La Presse Médicale
https://www.readbyqxmd.com/read/16185620/-usefulness-of-cochrane-collaboration-for-pediatric-cardiology
#6
REVIEW
Javier González-de Dios, Albert Balaguer-Santamaría, Carlos Ochoa-Sangrador
The Cochrane Collaboration provides growing and readily accessible resources to help ensure that medical decision-making is based on detailed, methodical, and up-to-date reviews of the best available evidence. We analyzed systematic reviews in the field of pediatric cardiology published by the Cochrane Collaboration's 50 Collaborative Review Groups. We found a total of 20 systematic reviews: 13 published by the Cochrane Neonatal Group, 6 by the Cochrane Heart Group, and 1 by the Cochrane Peripheral Vascular Disease Group...
September 2005: Revista Española de Cardiología
https://www.readbyqxmd.com/read/15194993/atrial-fibrillation-and-cardioembolic-stroke
#7
REVIEW
J M Ferro
The most disabling consequence of atrial fibrillation (AF) is stroke. In the elderly, AF is the single most important cause of stroke. The risk of stroke is increased at least 6-fold in subjects with AF. Strokes in patients with AF are in general severe, associated with higher risk of fatality and prone to early and long-term recurrence. The cardiac origin of stroke can be strongly suspected by anamnesis, clinical examination and findings on neuroimaging. Paroxysmal AF is an important cause of brain embolism, that is often difficult to document...
April 2004: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/15136304/risk-factors-for-venous-thromboembolism-in-hospitalized-patients-with-acute-medical-illness-analysis-of-the-medenox-study
#8
Raza Alikhan, Alexander T Cohen, Sophie Combe, Meyer M Samama, Louis Desjardins, Amiram Eldor, Charles Janbon, Alain Leizorovicz, Carl-Gustav Olsson, Alexander G G Turpie
BACKGROUND: There is limited information about risk factors for venous thromboembolism (VTE) in acutely ill hospitalized general medical patients. METHODS: An international, randomized, double-masked, placebo-controlled trial (MEDENOX) has previously been conducted in 1102 acutely ill, immobilized general medical patients and has shown the efficacy of using a low-molecular-weight heparin, enoxaparin sodium, in preventing thrombosis. We performed logistic regression analysis to evaluate the independent nature of different types of acute medical illness (heart failure, respiratory failure, infection, rheumatic disorder, and inflammatory bowel disease) and predefined factors (chronic heart and respiratory failure, age, previous VTE, and cancer) as risk factors for VTE...
May 10, 2004: Archives of Internal Medicine
https://www.readbyqxmd.com/read/12945875/prevention-of-venous-thromboembolism-in-medical-patients-with-enoxaparin-a-subgroup-analysis-of-the-medenox-study
#9
RANDOMIZED CONTROLLED TRIAL
Raza Alikhan, Alexander T Cohen, Sophie Combe, Meyer M Samama, Louis Desjardins, Amiram Eldor, Charles Janbon, Alain Leizorovicz, Carl-Gustav Olsson, Alexander G G Turpie
The Medical Patients with Enoxaparin (MEDENOX) trial was a randomized, placebo-controlled study that defined the risk of venous thromboembolism (VTE) in acutely ill, immobilized, general medical patients and the efficacy of the low-molecular-weight heparin, enoxaparin, in preventing thrombosis. We performed a post-hoc analysis to evaluate the effect of 40 mg enoxaparin once daily on MEDENOX patient outcome in different types of acute medical illness (heart failure, respiratory failure, infection, rheumatic disorder and inflammatory bowel disease) and pre-defined risk factors (chronic heart and chronic respiratory failure, age, immobility, previous VTE and cancer)...
June 2003: Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis
https://www.readbyqxmd.com/read/12428993/atrial-fibrillation-in-the-elderly-facts-and-management
#10
REVIEW
Guy Chatap, Karine Giraud, Jean-Pierre Vincent
Although atrial fibrillation is not widely known by the general public, in developed countries it is the most common arrhythmia. The incidence increases markedly with advancing age. Thus, with the growing proportion of elderly individuals, atrial fibrillation will come to represent a significant medical and socioeconomic problem. The consequences of atrial fibrillation have the greatest impact. The risk of thromboembolism is well known; other outcomes of atrial fibrillation are less well recognised, such as its relationship with dementia, depression and death...
2002: Drugs & Aging
https://www.readbyqxmd.com/read/11279381/-atrial-fibrillation-and-thromboembolic-events-prevention-state-of-the-art
#11
REVIEW
S Matteoli, M Trappolini, F M Chillotti
Atrial Fibrillation (AF) is a common cardiac arrhythmia and stroke is its most devasting complication. The rate of ischemic stroke among people with AF is approximately six times that of people without AF and varies importantely with coexistent cardiovascular diseases; therefore stratification of AF patients into those at high and low risk of thromboembolism has become a crucial determinant of optimal antithrombotic prophylaxis. Multivaria-te analyses of prospective studies consistently show prior TIA/stroke, diabetes, age, heart failure to be independently predictive of stroke; left ventricular dysfunction is also strongly associated with stroke risk...
February 2001: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/11206019/thrombosis-prophylaxis-in-the-acutely-ill-medical-patient-insights-from-the-prophylaxis-in-medical-patients-with-enoxaparin-medenox-trial
#12
RANDOMIZED CONTROLLED TRIAL
A G Turpie
The clinical benefit and cost-effectiveness of routine thromboprophylaxis in surgical patients has been well documented, but use of this approach in general medical patients remains controversial. Following is an overview of major insights from the prophylaxis in Medical patients with Enoxaparin (MEDENOX) trial, which was undertaken to evaluate the efficacy of 2 dosage regimens of the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism in acutely ill medical patients. MEDENOX was a prospective, double-blind, randomized, placebo-controlled trial, which enrolled 1,102 hospitalized patients from 68 centers in 9 countries...
December 28, 2000: American Journal of Cardiology
https://www.readbyqxmd.com/read/8607390/atrial-fibrillation-anticoagulation-and-stroke
#13
REVIEW
J Morley, R Marinchak, S J Rials, P Kowey
There is a demonstrated statistical association between atrial fibrillation, rheumatic valvular disease, and embolic stroke. This article assesses the results of 6 major clinical trials (AFASAK, BAATAF, SPINAF, SPAF [parts I and II], CAFA and EAFTA--see text for trial names). Multivariate analysis revealed 4 independent clinical features that identified patients with atrial fibrillation at an increased risk for stroke: hypertension, increasing age, previous transient ischemic attack, and diabetes mellitus. Without anticoagulation therapy, patients with any of these risk factors had a 4% annual risk of stroke...
January 25, 1996: American Journal of Cardiology
https://www.readbyqxmd.com/read/8020029/-atrial-fibrillation-incidence-and-prognostic-factors-of-embolic-risk
#14
REVIEW
G Di Pasquale, M A Ribani, S Urbinati, P Passarelli, G Pinelli
Atrial fibrillation (AF) carries a high risk of systemic embolism, in particular stroke. This is true not only when AF is associated with rheumatic valvular heart disease, but also in the so-called nonvalvular AF (NVAF). The recent randomized clinical trials assessing antithrombotic therapy as primary prevention in NVAF have shown that, untreated, disabling stroke occurs in 2.5%/year, ischemic stroke in 5%/year, stroke and transient ischemic attack in 7%/year, and stroke, transient ischemic attack and silent stroke in > 7%/year...
December 1993: Cardiologia: Bollettino Della Società Italiana di Cardiologia
https://www.readbyqxmd.com/read/7635036/warfarin-or-aspirin-for-non-rheumatic-atrial-fibrillation
#15
REVIEW
(no author information available yet)
Atrial fibrillation (AF) predisposes to stroke, particularly in patients with rheumatic heart disease, congestive heart failure, arterial hypertension, diabetes mellitus or uncontrolled thyrotoxicosis. In those with rheumatic heart disease it is usual to give warfarin to reduce the incidence of stroke, although there has been no randomised controlled trial on which to base this approach. Whether patients with non-rheumatic AF should be anticoagulated was unclear when we tackled this subject five years ago. This article reviews the evidence from recent randomised controlled trials and considers whether anticoagulation with warfarin, or antiplatelet therapy with aspirin, should now be routine for patients with non-rheumatic AF...
August 18, 1994: Drug and Therapeutics Bulletin
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"